Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1378021 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson’s disease. Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and selective (vs. A1) antagonist 11 h, orally active in the rat haloperidol-induced catalepsy model. We further optimized this lead to the methoxyethoxyethyl ether 12a (SCH 420814), which shows broad selectivity, good pharmacokinetic properties, and excellent in vivo activity.
Graphical abstractStarting from the known adenosine A2A antagonist SCH 58261, SAR-guided structural optimization led to SCH 420814, which is a potent and selective A2A antagonist, with good pharmacokinetics and excellent oral activity in rodent models of Parkinson’s disease.Figure optionsDownload full-size imageDownload as PowerPoint slide